DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.
- Published In:
- Cardiovascular drugs and therapy, 28(5), 425-32 (2014)
- Authors:
- Dai, Yao, Dai, Dongsheng, Wang, Xianwei, Ding, Zufeng, Mehta, Jawahar L
- Database ID:
- RPEP-02363
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-02363APA
Dai, Yao; Dai, Dongsheng; Wang, Xianwei; Ding, Zufeng; Mehta, Jawahar L. (2014). DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.. Cardiovascular drugs and therapy, 28(5), 425-32. https://doi.org/10.1007/s10557-014-6539-4
MLA
Dai, Yao, et al. "DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.." Cardiovascular drugs and therapy, 2014. https://doi.org/10.1007/s10557-014-6539-4
RethinkPeptides
RethinkPeptides Research Database. "DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-..." RPEP-02363. Retrieved from https://rethinkpeptides.com/research/dai-2014-dpp4-inhibitors-repress-nlrp3
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.